Connect with us

General Health

Electronic Clinical Outcome Assessment Solutions Market Outlook to 2027 – Global Analysis and Forecasts By Delivery Mode (Licensed Enterprises, Web Hosted, Cloud Based)

Published

on

Press Release

New Report Published by The Insight Partners on “Electronic Clinical Outcome Assessment Solutions Market”, negates drastic deviation in the market estimation and is used to estimate the Electronic Clinical Outcome Assessment Solutions Market size and forecasts till 2027.

The market of electronic clinical outcome assessment solutions market is anticipated to grow with a significant rate in the coming years, owing to factors such as, rising need for integrated data capture system of clinical experimental educations by huge pharmaceutical and biopharmaceutical companies, Increasing focus and demand for cloud based services. The data capturing via eCOA platforms improves quality of information received, various technologies of new drug development procedures leaning towards eCOA in the healthcare industry in Asia Pacific and Europe are expected to offer growth opportunities for the players operating in the market.

Electronic Clinical Outcome Assessments (eCOA) employs technology such as smartphones, tablets, and personal computers to allow patients, clinicians, and their caregivers to directly report outcomes. Today, eCOA produces highly accurate data that allows for a better understanding of the patient experience in clinical trials and ultimately helps simplify the path to approval.

 Get Sample report at – https://www.theinsightpartners.com/sample/TIPHC00002237

 The Report Contains-

  • To identify emerging players with the desirable extreme product portfolio
  • To setup vigorous counter schemes to obtain competitive benefits
  • To discover new beginners of partners in the target analytics
  • To know the main areas of Electronic Clinical Outcome Assessment Solutions industry
  • To plan partnerships and accession perfectly
  • To traverse business capabilities and scope

The Electronic Clinical Outcome Assessment Solutions Market report give a 360-degree holistic view of the market and highlights the key developments, drivers, restraints ,opportunities and future trends with an impact analysis of these market dynamics for short-term, mid-term and long-term during the forecast period. In addition, the report also provides profiles of major companies along with detailed of products/service portfolio, SWOT analysis, financial facts and key developments from the past three years.

Top Companies Listed are-

  • PAREXEL INTERNATIONAL CORPORATION
  • ERT CLINICAL
  • BIOCLINICA
  • IBM WATSON HEALTH
  • CRF HEALTH
  • MEDIDATA SOLUTIONS, INC.
  • CLINICAL SOLUTIONS LLC.
  • OMNICOMM SYSTEMS, INC
  • ORACLE CORPORATION
  • ICON PLC

 The Global Electronic Clinical Outcome Assessment Solutions Market report endows you with the plentiful insights and business solutions that will help you attain the new horizons of success. The scope of this market report extends from market scenarios to comparative pricing between major players, cost and profit of the specified market regions. While preparing report, markets on the local, regional and global level have been explored. The report is valuable for both customary and emerging market players in the industry and provides in-depth market insights. The Global Electronic Clinical Outcome Assessment Solutions Market report offers analysis of the top industry players, Strategic recommendations for the new entrants in this market, Company profiling with detailed strategies, financials, and recent developments, Supply chain trends mapping the latest technological advancements.

Buy Complete Report at – https://www.theinsightpartners.com/buy/TIPHC00002237

 About Us – The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

Contact us –

 Phone : +1-646-491-9876

Email Id : [email protected]

Website: https://www.theinsightpartners.com

This post was originally published on Health News Office

Continue Reading

General Health

Proliferative Diabetic Retinopathy Market Initially Had Gained A Revenue Worth US$1,000 mn by the End of 2026

Published

on

Press Release

Transparency Market Research (TMR) found that the global proliferative diabetic retinopathy market has a considerably strong competitive landscape due to the influence of a few leading players. Allergan Plc, Regeneron Pharmaceuticals, Inc., Merck KGaA, Cipla, Ltd., Genentech, Inc. (Roche Holdings), Novartis AG, and Pfizer, Inc., are some of the companies upholding leading shares in the market. To stand out from this market competition, the large and small-scale market players are putting efforts to introduce new offers. These players are concentrating on bringing forth immense improvements in the products to sustain in the cutthroat competition of the market. Also, new companies are also concentrating on offering low-priced advanced products.

According to TMR, the global proliferative diabetic retinopathy market is expected to swell with a stellar CAGR of 9.5% over the forecast period from 2017 to 2026. Furthermore, the global proliferative diabetic retinopathy market is projected to reach a value of US$1,000 mn by the end of 2026. Based on distribution channel, the global proliferative diabetic retinopathy market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, hospital pharmacies accomplished maximum sale of drugs in proliferative diabetic retinopathy market.

U.S. led the North America proliferative diabetic retinopathy market in 2016. This is owing to rising incidences of irreversible blindness, which is a severe condition arising from diabetic retinopathy. Growing prevalence of diabetes among the youth will further drive the market.

Request to View Sample of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40637

Increasing Prevalence of Diabetes, Propels the Growth of the Global Market

Growing number of baby boomers universally combined with increasing prevalence of diabetes will be the major factors for proliferative diabetic retinopathy market. Old-aged people are inclined to suffer from chronic disorders like diabetes along with age related macular degeneration (AMD). As stated by National Eye Institute (NEI), almost 5.4-mn populaces in the US will suffer from AMD in the near future.

Rising adoption of inactive lifestyle along with unhealthy diets has increased number of people suffering from obesity, consequently increasing prevalence of diabetes. Furthermore, aspects like uncontrolled glucose levels and blood pressure, non-compliance to treatment, and prolonged undiagnosed diabetes lead to incidence of proliferative diabetic retinopathy. Growing prevalence of eyesight loss owing to diabetes will boost the proliferative diabetic retinopathy market immensely.

Existence of associations like American Diabetes Association focusing towards generating awareness about proliferative diabetic retinopathy will drive the market. Numerous efforts are undertaken by domestic governments to decrease disorders occurrences. This can reduced by conducting plans like diabetic eye screening (DES) and numerous awareness campaigns, which will drive the proliferative diabetic retinopathy market. A rising demand for innovative diabetes treatments and advancements in R&D provides a huge impetus to the market. Such a growth graph is foretold to continue even in future for the global proliferative diabetic retinopathy market.

Shortage of skilled ophthalmologists combined with poor primary infrastructure in remote regions restraints the market. Moreover, lack of insurance facilities makes it difficult for patients to pay for their treatments. However, numerous new unorthodox diabetic treatments in the form of spiritual and ayurvedic channels are replacing the traditionally used ones. This could pave new way for the global proliferative diabetic retinopathy market, thus countering the major challenges.

This post was originally published on Health News Office

Continue Reading

General Health

Platelet Rich Plasma & Stem Cell Alopecia Treatment Market That Witnessed The Share Worth US$ 450 Mn by 2026

Published

on

Press Release

According to the report, the global platelet rich plasma & stem cell alopecia treatment market was valued at approximately US$ 250Mn in 2017. The market is anticipated to reach a value of US$ 450.5 Mn by 2026, expanding at a higher single digit CAGR during the forecast period. Rise in awareness about platelet rich plasma & stem cell alopecia treatment and increase in funding for alopecia treatment research and stem cell research are expected to augment the global market from 2018 to 2026. The global platelet rich plasma & stem cell alopecia treatment market is projected to expand, owing to a rise in the incidence of alopecia and technological advancements.

Rise in Awareness about Platelet Rich Plasma Therapies and Stem Cell Therapies is Propelling the Global Alopecia Treatment Market

The global platelet rich plasma & stem cell alopecia treatment market is expanding at a high growth rate, driven by an increase in awareness about platelet rich plasma & stem cell therapies for treating many types of alopecia. The prevalence of various types of hair loss is increasing rapidly across the world, due to a rise in the geriatric population, anxiety, vaccination, side effects of drugs, etc.. A rise in the incidence of autoimmune hair loss disorders such as alopecia is boosting the platelet rich plasma & stem cell alopecia treatment market. According to a report in the International Journal of Endocrinology and Metabolism, 2013, female pattern hair loss (FPHL), which is also known as female androgenetic alopecia, is a common condition afflicting millions of women across the world.

Increase in Funding for Alopecia Treatment Research and Stem Cell Research

Stem cells hold promise for the treatment and cure of more than 70 major diseases, including alopecia and other conditions that affect millions of people worldwide. Several private and government organizations are supporting funding for stem cell research. According to Change.org, Inc., in the U.S., 64% of people support federal funding of research on the treatment of chronic diseases using stem cells taken from human embryos. Internationally, stem cell research is supported by significant government investments, with Asia being one of the most favorable regions.

Stem cell research funding by the National Institutes of Health (NIH) has increased 17% from US$ 1.2 Bn in 2013 to US$ 1.5 Bn in 2016. In 2017, nonprofit organization Alopecia UK donated US$ 0.6 Mn to the University of the West of Scotland for the development of early treatment to prevent the progression of alopecia areata. Research conducted by the university aims at developing a treatment for alopecia areata using a nonchemical stem-cell based technology based on Nano vibrations known as Nano kicking.

Request to View Sample of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=55800

North America Dominates the Global Platelet Rich Plasma & Stem Cell Alopecia Treatment Market owing to a Rise in Technological Advancements and Prevalence of Alopecia

North America dominates the global platelet rich plasma & stem cell alopecia treatment market, owing to technological advancements, investments in research & development, and developed health care infrastructure. As per research, in 2015, 21% of women suffered from alopecia in the U.S, which supports the fact that alopecia has a higher prevalence in the country. Moreover, development of innovative products and increase in demand for products among the population in the region are contributing factors for the dominance of North America in the platelet rich plasma & stem cell alopecia treatment market.

Expansion in the Contract Research Industry Offers Significant Opportunities for Companies to Invest in Clinical Trials for Alopecia Treatment

Small and large biopharmaceutical companies have become increasingly reliant on contract research organizations (CRO) and other clinical services specialists to provide research services for their R&D operations. There are numerous government-funded medical and pharmaceutical institutions, with state-of the-art facilities, that can serve as ideal centers for multicentered clinical trials. Companies are expanding their footprints in developing countries, mainly in Asia Pacific. R&D costs in India are substantially lower as compared to those in developed countries. It is possible to conduct both new drug discovery research and novel drug delivery system programs at competitive rates. India offers cost efficiency, as the cost of conducting a trial in the country is 50% to 75% lower compared to that in the U.S.

This post was originally published on Health News Office

Continue Reading

General Health

Advanced (3D/4D) Visualization Systems Market Would Expand At A Starry CAGR of 6.4% Within the Forecast Period from 2016 to 2024

Published

on

Press Release

Transparency Market Research (TMR), the global advanced (3D/4D) visualization systems market is likely to expand with a steady CAGR of 6.4% within the forecast period from 2016 to 2024. The global advanced (3D/4D) visualization systems market is foreseen to be valued around worth US$3.2 bn by the end of forecast period.

On the basis of platform, the CT segment is estimated to lead the global advanced (3D/4D) visualization systems market in terms of highest revenue share. Geographically, North America region had accounted for maximum share in advanced (3D/4D) visualization systems market in 2015, due to emergence of improved healthcare system, rises in awareness among patients, solid regional economy, advancement in technology.

Read Report Overview –

https://www.transparencymarketresearch.com/advanced-3d-4d-visualization-systems.html

Ability to View Diagnostic Images in Real-time To Propel Demand

Medical professionals broadly draw in advanced (3D/4D) visualization systems to experience changes in body starting with one frame onto the next with the assistance of diagnostic pictures. The pictures could be seen progressively in real-time, along with the features to store, transfer, and share in 3D/4D format utilizing the innovation. Since 2015, the U.S. Food and Drug Administration (FDA) have made digitalization and the capacity of patient information mandatory. In addition, as per the U.S. Enumeration Bureau, an impressive number of regional population is likely to be incorporated into the classification of older individuals around 65 years or more. These components could make a platform to accommodate the rising development of the advanced (3D/4D) visualization systems market.

Request to View Sample of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2547

Industrial advancements have a distinct spot in businesses as exact and precise imaging is a genuine necessity in the present medical world. Besides, an increase in geriatric population, the rising number of different ailments could catalyze the demand for novel diagnostic systems, for example, advanced (3D/4D) visualization systems.

High Installation Cost to Hinder Growth of Market

Owing to high installation and setup costs, different end use industries are likely to be discouraged from the usage of advanced (3D/4D) visualization systems. Nevertheless, this limitation of the advanced (3D/4D) visualization systems market can be countered with significant improvements in healthcare sectors in the major regions. Besides, the improvement in healthcare infrastructure, rising focus on advancements in the medical sector, and an enormous pool of underserved individuals suffering from various ailments are forecasted to provide incredible scope for players to achieve success in the global advanced (3D/4D) visualization systems market.

Several growth opportunities are expected to arise in the coming years in the global advanced (3D/4D) visualization systems market because of the increasing number of customers, accessibility of multi-modality highlights, and incorporation of PACS.

This post was originally published on Health News Office

Continue Reading

Trending